Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause

Muhammad Shahzeb Khan, Javed Butler, Stefan D. Anker, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, James L. Januzzi, Ileana L. Piña, Michael Böhm, Piotr Ponikowski, Subodh Verma, Martina Brueckmann, Ola Vedin, Cordula Zeller, Faiez Zannad, Milton Packer

Open source

DOI: 10.1161/jaha.122.027652
Published: 1
Container: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1161/jaha.122.027652,
  title = {Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause},
  author = {Muhammad Shahzeb Khan and Javed Butler and Stefan D. Anker and Gerasimos Filippatos and João Pedro Ferreira and Stuart J. Pocock and James L. Januzzi and Ileana L. Piña and Michael Böhm and Piotr Ponikowski and Subodh Verma and Martina Brueckmann and Ola Vedin and Cordula Zeller and Faiez Zannad and Milton Packer},
  year = {2023},
  journal = {Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease},
  doi = {10.1161/jaha.122.027652},
  url = {https://doi.org/10.1161/jaha.122.027652}
}

RIS

TY  - JOUR
TI  - Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
AU  - Muhammad Shahzeb Khan
AU  - Javed Butler
AU  - Stefan D. Anker
AU  - Gerasimos Filippatos
AU  - João Pedro Ferreira
AU  - Stuart J. Pocock
AU  - James L. Januzzi
AU  - Ileana L. Piña
AU  - Michael Böhm
AU  - Piotr Ponikowski
AU  - Subodh Verma
AU  - Martina Brueckmann
AU  - Ola Vedin
AU  - Cordula Zeller
AU  - Faiez Zannad
AU  - Milton Packer
PY  - 2023
JO  - Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
DO  - 10.1161/jaha.122.027652
UR  - https://doi.org/10.1161/jaha.122.027652
ER  -

APA

Khan, M. S., Butler, J., Anker, S. D., Filippatos, G., Ferreira, J. P., Pocock, S. J., Januzzi, J. L., Piña, I. L., Böhm, M., Ponikowski, P., Verma, S., Brueckmann, M., Vedin, O., Zeller, C., Zannad, F., & Packer, M. (2023). Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. https://doi.org/10.1161/jaha.122.027652

Source records

doaj · retrieved 2026-09-26T08:30:56.797Z